Tempus Q2 2026 revenue rises 22% to USD 382.5M; full-year guidance about USD 1.6B

Tempus AI

Second-quarter revenue grew 22% as oncology test volumes rose 31% and data-licensing (Insights) revenue grew 36%. Tempus raised 2026 revenue guidance to USD 1.595-1.605B, kept its USD 65M adjusted EBITDA target, and delivered its first oncology foundation model to AstraZeneca.

• Diagnostics USD 289.3M (+20%); data and applications USD 93.2M (+28%).
• Recurrence (MRD) tests reached about 9,000 in the quarter, up from 6,500.
• Raised USD 460M in convertible notes and signed about USD 200M of new data deals.